La chaîne d'options affiche les données clés des options sur actions de Unicycive Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Unicycive Therapeutics..

Unicycive Therapeutics (NASDAQ:UNCY) Stock, Chaîne d'Options

UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics Inc

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cloudflare.com%2F&amp;esheet=54284529&amp;newsitemid=20250701003239&amp;lan=en-US&amp;anchor=Cloudflare%2C+Inc.&amp;index=1&amp;md5=47ff461d295196d8e90bef72765f97e7">Cloudflare, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), the leading connectivity cloud company, today announced it is now the first Internet infrastructure provider to block AI crawlers accessing content without permission or compensation, by default. Starting today, website owners can choose if they want AI crawlers to access their content, and decide how AI companies can use it. AI companies can also now clearly state their purpose – if their crawlers are used for training, inference, or search – to help website owners decide which crawlers to allow. Cloudflare's new default setting is the first step toward a more sustainable future for both content creators and AI innovators.
For decades, the Internet has operated on a simple exchange: search engines index content and direct users back to original websites, generating traffic and ad revenue for websites of all sizes. This cycle rewards creators that produce quality content with money and a following, while helping users discover new and relevant information. That model is now broken. AI crawlers collect content like text, articles, and images to generate answers, without sending visitors to the original source – depriving content creators of revenue, and the satisfaction of knowing someone is viewing their content. If the incentive to create original, quality content disappears, society ends up losing, and the future of the Internet is at risk.

News

Cloudflare Blocks AI Crawlers by Default to Protect Creators and Preserve the Open Web

<a href="https://www.globenewswire.com/Tracker?data=tGz0dw0pR_P89fCX0FX2-gR7RuVgBcSWd46s9xalhYWIklGKuAnK-r-Ohi8VeH5np2Q2ZXOURr8mrEDOC66KWg==">atai Life Sciences</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) ("atai"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and <a href="https://www.globenewswire.com/Tracker?data=wW0gyjlj2Y1nMJJXwZPe4EYcRlDWYB_3agsCfQdOeEepSi_1-4Xdko8zwLcguFNvAfFkBqkOtR0p-2DFabXKeQhVvd9gwJgJoRftm7aYxhM=">Beckley Psytech Limited</a>&nbsp;("Beckley Psytech"), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints. At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean decrease of 11.1 points from baseline compared to a 5.8 point reduction in the 0.3 mg comparator group (p = 0.0038). For the key secondary efficacy endpoints, a single 8 mg dose of BPL-003 also showed significant improvement at Day 29, with a mean MADRS score reduction of 12.1 points (p=0.0025 for change vs. 0.3 mg control). Notably, both the 8mg and 12mg doses of BPL-003 showed statistically significant improvements in MADRS scores as early as one day after dosing, with effects generally maintained out to Week 8.
Safety and efficacy results from this study support the selection of the 8 mg dose of BPL-003 for advancement into Phase 3 clinical studies. atai and Beckley Psytech plan to engage with the U.S. Food and Drug Administration (FDA) and other applicable agencies regarding the Phase 3 trial design for patients with treatment-resistant depression in the coming months.
With these positive Phase 2b results, the pre-agreed success criteria for the proposed strategic combination between atai and Beckley Psytech, which was <a href="https://www.globenewswire.com/Tracker?data=Lt5j5BhiTtHS91OwzC43YoUVuGJaUtezdgq72Y5stYLZkHr4bb9o577WWVdJxus65y-bxktrE-m2HzVPBckcZGIo9XaRX-W5NvSz-VAyy2x2u4cfn9aY-9bPS0KD2JyxcmZZWJbpb4JuhEW5rVBliZZUWUU5eg5ihDS8sBwsqHvblHLEnC_9lIACrn6IvlSAylV04CEThCH-uPz_ccyGFx5oNBbVUDWGnlC6IVPw-EE=">announced in June 2025,</a> has been achieved and the strategic combination is now expected to progress to atai shareholder approval stage. The atai Beckley combination is expected to create a global leader in short time in-clinic psychedelic-based mental health therapies.
Cosmo Feilding Mellen, Chief Executive Officer and Co-Founder of Beckley Psytech, said: "The achievement of our primary and secondary endpoints in this study represents an important milestone in the development of BPL-003 and reinforces its potential to be a viable treatment option for patients and healthcare systems. We are particularly encouraged that a single 8 mg or 12 mg dose of BPL-003 showed rapid and durable efficacy results, favourable tolerability and a short time in-clinic, giving us important flexibility in optimising the design of future trials. Thank you to all of the patients and study partners who participated in this study - we now look forward to preparing for end-of-Phase 2 meetings with regulators and moving forward with our strategic combination with atai Life Sciences to form atai Beckley, a global leader in psychedelic-based mental health treatments."
The Phase 2b clinical study was conducted at 38 sites across six countries and enrolled a total of 193 patients with moderate-to-severe TRD (defined as non-response to two or more prior treatments in the current depressive episode) (<a href="https://www.globenewswire.com/Tracker?data=kSI-UnKZ0DWeSwYIsB0N090rWka30y2wA4jPYu0nejPg7OVIE6Y9-lDi86fU3j9pns2LTvJDSceDpY7US5Ca9x1v_eZEapoW8PDPBYTLRgoNJwv7P7HNhAmrRG2HXGOJcTrJfssR6lmmu6k1ezzAxw==">NCT05870540</a>). It is the largest controlled clinical study to investigate mebufotenin and the only blinded Phase 2b study of mebufotenin to include the United States. Patients were randomized to receive a single 12 mg (n=73), 8 mg (n=46), or 0.3 mg comparator (n=74) dose of BPL-003 and were followed for eight weeks with efficacy assessments conducted by centralised, blinded raters using the MADRS at Day 2, Day 8, Day 29 and Day 57.
Key efficacy findings:
<ul>
<li>A single 12 mg dose of BPL-003 led to a mean reduction in MADRS score from baseline of 11.1 points compared with 5.8 points in the 0.3 mg comparator arm (p=0.0038) at Day 29, with the 8 mg dose arm showing a mean MADRS reduction from baseline of 12.1 points versus the 0.3mg comparator arm (p=0.0025) at that same timepoint.</li>
<li>The 8 mg and 12 mg doses of BPL-003 demonstrated equivalent efficacy suggesting the 8 mg dose may be sufficient to achieve therapeutic benefit from a single dose.</li>
<li>The difference in MADRS scores between the 8 mg and 12 mg doses versus the 0.3 mg dose were statistically significant in both active arms from as early as Day 2, with mean MADRS reductions from baseline of 8.8 points in the 8 mg group and 8.9 points in the 12 mg group observed at that timepoint, compared to a reduction from baseline of 3.9 points in the 0.3 mg group. These mean reductions from baseline increased to 11.1 points in the 8 mg group and 10.8 points in the 12 mg group at Day 8.</li>
<li>A durable effect was also observed for both higher doses, with the 8 mg group showing a mean reduction of 10.8 points from baseline at Day 57 and the 12 mg group showing a mean reduction of 10.2 points from baseline compared with the 0.3 mg group (5.2 point reduction). These findings highlight the potential of BPL-003 to be a durable treatment for patients with TRD.</li>
</ul>
Key safety findings:
<ul>
<li>BPL-003 was generally well-tolerated at all doses. More than 99% of treatment-emergent adverse events (TEAEs) were mild or moderate and there were no drug-related serious adverse events (SAEs).</li>
<li>Dose related increases in administration site discomfort, nausea, headache, blood pressure and anxiety suggest the 8mg dose was better tolerated than the 12mg dose.</li>
<li>No participants in the 8 mg nor 12 mg arms had any instance of treatment-emergent suicidal intent or behaviour, indicating no suicide-related safety signal observed to date.</li>
<li>The average time to meet readiness for discharge criteria across all arms was within two hours of dosing, with the majority of patients deemed ready for discharge at the 90 minutes post-dose assessment. This, alongside the administration of BPL-003 via a previously approved nasal spray device, supports the potential of BPL-003 to fit within the existing interventional psychiatry treatment paradigm that has been successfully established by Spravato&#xAE;.</li>
<li>The study had a low drop-out rate with 90% of patients completing the core study.</li>
<li>These findings suggest a favourable tolerability profile which are consistent with earlier Phase 1 and Phase 2a studies of BPL-003, as well as other psychedelic studies within the class.</li>
</ul>
Additional data from the core study is expected to be shared through publications and medical meetings in the future.

ATAI

Atai and Beckley Report Depression Trial Results, Pave Way for Psychedelic-Based Mental Health Breakthrough

Venture Global's Calcasieu Pass LNG Facility Upgraded To Investment-Grade 'BBB-' By S&P After Commercial Launch, LRT Completion

Amid the turmoil and uncertainties in recent months, U.S. equity markets have reached a staggering new milestone, with market capitalization hitting $63.8 trillion.
What Happened: On Monday, in a post on X, The Kobeissi Letter shared recent data from Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) showcasing the remarkable surge in valuations in the U.S. equity markets over the past five years.
&#8220;This is incredible,&#8221; the post says, adding that the &#8220;U.S. market has never been this large,&#8221; after doubling from under $31 trillion in 2020. 
See Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46166959/sp500-stocks-outlook-etf-analysis">This S&amp;P 500 ETF Saw A 30-Month Buying Spree — Now It&#8217;s Over</a>
For comparison, the post notes that it took eight years, from 2012 to 2020, to double in value during the previous cycle, clearly highlighting the acceleration being witnessed in U.S. equity markets, which comes despite substantial trade, tariffs, and geopolitical uncertainties.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This is incredible: The US stock market has never been this large. Total US public equity market capitalization hit a record $63.8 TRILLION, according to Goldman Sachs data. That's DOUBLE the size it was 5 years ago. By comparison, previously it took 8 years, from 2012 to… <a href="https://t.co/q72isq7XV4">pic.twitter.com/q72isq7XV4</a>
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1939838864471773200?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
To further emphasize the magnitude of this milestone, the post says that U.S. markets are now &#8220;three times larger than Europe&#8217;s,&#8221; while being larger than the &#8220;combined market size of Europe, China, Hong Kong, Japan, and India.&#8221;
&#8220;Mind-blowing numbers,&#8221; it says in conclusion.
Why It Matters: The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), touched a fresh intraday high on Monday, hitting 6,215.08 points. 
Leading analysts, such as Ryan Detrick, note that this is the first time since 1950 that the index has hit an all-time high in June.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Stocks just made a new all-time high in June. Stocks have never peaked in June. &#x1f9d0; <a href="https://t.co/ItYm8vmOog">pic.twitter.com/ItYm8vmOog</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1938949133832003645?ref_src=twsrc%5Etfw">June 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Last week, the index flashed a sign that traders refer to as a &#8220;Golden Cross,&#8221; when the 50-day moving average rises above the 200-day moving average, often seen as a sign of momentum picking up and a <a href="https://www.benzinga.com/markets/economic-data/25/06/46124290/sp-500-hits-record-highs-and-history-says-the-best-is-yet-to-come">new high being underway</a>.
Analysts note that since World War 2, the Golden Cross has appeared 37 times, and three out of four times, it has led to gains.
Price Action: The S&amp;P 500 was up 0.52% on Monday, trading at 6,204.95 points, while the Nasdaq ended up 0.47%, at 20,369.73, followed by the Dow Jones at 44,094.77, up 0.63%.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46188576/sp-hits-record-high-at-the-end-of-q2-investor-sentiment-improves-fear-index-remains-in-greed-zone">S&amp;P Hits Record High At The End Of Q2: Investor Sentiment Improves, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

US Stock Market Hits Record $63.8 Trillion, Doubling In 5 Years: Now Bigger Than Europe, China, Japan, India Combined

Two Chinese artificial intelligence chip startups, Moore Threads and MetaX, are planning to raise a combined 12 billion yuan ($1.65 billion) through initial public offerings (IPOs). 
What Happened: The two companies are betting on the U.S. export restrictions to boost the demand for their products in China, Reuters reported. 
Moore Threads, based in Beijing, aims to raise 8 billion yuan, while MetaX, based in Shanghai, is looking to raise 3.9 billion yuan. Both companies are planning to list on the STAR Market, the tech-focused board of the Shanghai Stock Exchange
These fundraising plans highlight the increasing efforts of Chinese chipmakers to capitalize on Beijing&#8217;s drive to develop domestic champions in graphics processing units (GPUs), which are crucial for AI development.
See Also: <a href="https://benzinga.com/markets/tech/25/06/46159877/steve-jobs-once-spent-two-weeks-choosing-a-washing-machine-for-his-palo-alto-home-and-he-got-more-thrill-out-of-it-than-any-piece-of-high-tech-in-ages">Steve Jobs Once Spent Two Weeks Choosing A Washing Machine For His Palo Alto Home And He Got More &#8216;Thrill&#8217; Out Of It Than Any Piece Of High Tech In Ages &#8211; Benzinga</a>
The U.S. has been tightening export restrictions on China, with the latest rules implemented in April banning the shipment of Nvidia&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) H20 chips, one of its most popular chips, to China. These restrictions have led to a sense of urgency in Beijing to develop domestic chip champions.
Both Moore Threads and MetaX have cited U.S. sanctions as a major risk to their development, but have also emphasized that the restrictions could create significant market opportunities. The two companies design GPUs to compete with Nvidia products and have reported significant losses over the last three years, largely attributed to heavy research and development spending.
Why It Matters: The move by Moore Threads and MetaX to go public amid U.S. export sanctions is part of a larger trend of Chinese companies seeking to <a href="https://www.benzinga.com/markets/equities/25/03/44350873/nvidia-faces-new-ai-challenge-as-chinese-start-up-unveils-framework-to-cut-reliance-on-its-gpus">reduce their reliance</a> on foreign chipmakers. In May, Alibaba (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), and Tencent (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) began switching to <a href="https://www.benzinga.com/markets/asia/25/05/45692725/alibaba-and-baidu-turn-to-chinese-ai-chips-as-us-sanctions-squeeze-nvidia-supply">homegrown chips</a> as U.S. export controls and a dwindling stockpile of Nvidia processors eroded their ambitions. 
The move also aligns with China&#8217;s broader push for <a href="https://www.benzinga.com/government/regulations/25/05/45298562/chipmakers-enter-bullish-seasonal-window-5-stocks-that-could-outperform">self-sufficiency in chips</a>, with major Chinese automakers aiming for 100% domestic chip supply by 2027. This push is being <a href="https://www.benzinga.com/markets/equities/25/06/45966176/after-nvidia-pauses-china-outlook-top-chinese-automakers-race-to-ditch-foreign-chips-aim-for-100-domestic-supply-by-2027-report">shepherded</a> by China&#8217;s Ministry of Industry and Information Technology, which regularly requires self-assessments of domestic chip adoption rates.
Read Next: <a href="https://benzinga.com/markets/tech/25/06/46186013/mark-zuckerberg-once-predicted-that-this-technology-would-replace-your-phone-a-decade-later-how-far-">Mark Zuckerberg Once Predicted That This Technology Would Replace Your Phone — A Decade Later, How Far Is Meta From Delivering On A &#8216;More Natural&#8217; Future</a>
Photo: Maxx-Studio On Shutterstock

BABA

BIDU

NVDA

TCEHY

Nvidia's Chinese Rivals Look To Cash In On US Tech Ban: Moore Threads, MetaX Plot $1.65 Billion IPO

Investment advisor Ross Gerber criticized Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) board members on Tuesday for remaining silent as President Donald Trump launched a scathing attack on CEO Elon Musk and federal subsidies supporting his company.
What Happened: &#8220;Sadly true and it seems Elon is destined to find out who is more powerful. Not a peep from the Tesla BOD of this absurd attack on the President he enabled,&#8221; wrote Gerber, CEO of Gerber Kawasaki Wealth &amp; Investment Management, on social media platform X.
Gerber&#8217;s comments followed Trump&#8217;s <a href="https://www.benzinga.com/markets/equities/25/07/46187311/trump-says-elon-musk-would-close-up-shop-and-head-back-home-to-south-africa-without-subsidies-no-more-rocket-launches-satellites-or-electric-car">Truth Social post claiming Musk</a> &#8220;may get more subsidy than any human being in history, by far&#8221; and suggesting &#8220;without subsidies, Elon would probably have to close up shop and head back home to South Africa.&#8221; 
Trump added that eliminating support would mean &#8220;no more Rocket launches, Satellites, or Electric Car Production,&#8221; while the country &#8220;would save a fortune.&#8221;
The president specifically recommended that the Department of Government Efficiency (DOGE), which Musk previously headed, examine billions in subsidies flowing to his companies.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Sadly true and it seems Elon is destined to find out who is more powerful. Not a peep from the Tesla BOD of this absurd attack on the President he enabled. <a href="https://t.co/8Ae4o39zJD">https://t.co/8Ae4o39zJD</a>
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1939930759348863132?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46189000/palantir-is-building-the-next-aws-says-top-exec-urges-startups-to-build-on-pltr-to-tackle-more-valuable-problems-than-amazon-solved">Palantir Is Building The Next AWS, Says Top Exec: Urges Startups To Build On PLTR To Tackle &#8216;More Valuable&#8217; Problems Than Amazon Solved</a>
Why It Matters: The public feud marks a dramatic reversal between former allies. Musk <a href="https://www.benzinga.com/markets/equities/25/07/46187311/trump-says-elon-musk-would-close-up-shop-and-head-back-home-to-south-africa-without-subsidies-no-more-rocket-launches-satellites-or-electric-car">reportedly contributed over $250 million to Trump&#8217;s 2024 campaign</a> before departing the administration in June amid disagreements over Trump&#8217;s &#8220;Big Beautiful Bill&#8221; spending package.
Tesla faces <a href="https://www.benzinga.com/markets/tech/25/06/46162850/tesla-sales-in-canada-have-dropped-to-nearly-zero-says-researcher-expects-elon-musk-led-ev-giant-may-report-losses-starting-2026">mounting operational challenges</a> that compound political tensions. Canadian sales plummeted 87% in Quebec during the first quarter of 2025, according to researcher Troy Teslike, who warned the company may report GAAP losses starting in the first quarter of 2026. Tesla continues operating 35 Canadian stores despite near-zero sales.
Gerber has been a vocal Tesla critic, recently dumping over 20,000 shares in <a href="https://www.benzinga.com/25/05/45559223/ross-gerber-weighs-in-on-tesla-amid-elon-musks-five-year-commitment-to-ev-giant-seems-like-elon-mightve-gotten-my-message">the first quarter of 2025</a>. He previously blamed the board for &#8220;negligence&#8221; regarding brand damage from Musk&#8217;s political activities and called for leadership changes.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46188699/goldman-sachs-now-expects-3-fed-rate-cuts-in-2025-amid-weak-jobs-data-modest-trump-tariff-effects">Goldman Sachs Now Expects 3 Fed Rate Cuts In 2025 Amid Weak Jobs Data, Modest Trump Tariff Effects</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Politics

TSLA

Ross Gerber Says Elon Musk 'Enabled' The President As Trump Slams TSLA CEO Over Subsidies: Calls Out Tesla Board's Silence On 'Absurd Attack'

The Company delivered 24,925 vehicles in June 2025, representing an increase of 17.5% year-over-year. The deliveries consisted of 14,593 vehicles from the Company's premium smart electric vehicle brand NIO, 6,400 vehicles from the Company's family-oriented smart electric vehicle brand ONVO, and 3,932 vehicles from the Company's small smart high-end electric car brand FIREFLY. The Company delivered 72,056 vehicles in the second quarter of 2025, representing an increase of 25.6% year-over-year. Cumulative deliveries reached 785,714 as of June 30, 2025.
NIO's products have been highly recognized in the 2025 J.D. Power studies. The ET5 and ET5T ranked first among mid-size battery electric sedans in the China NEV-IQS study, while the EC6 claimed the top spot in the premium BEV segment in the China NEV-APEAL study. With superior product quality and exceptional user satisfaction, NIO has secured first place in its segment in J.D. Power's quality research for seven consecutive years since 2019.

NIO Delivers 24,925 Vehicles In June, Up 17.5% YoY; Q2 Deliveries Up 25.6% YoY To 72,056 Vehicles

Shares of Thumzup Media Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) rose sharply in today's pre-market trading after the company announced a $6.5 million <a href="https://www.benzinga.com/quote/TZUP">registered direct offering</a>.
Thumzup Media shares jumped 20.4% to $8.45 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>BioNexus Gene Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) surged 238.7% to $10.60 in pre-market trading after gaining 12% on Monday.</li>
<li>Wolfspeed, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) gained 90.8% to $0.7639 in pre-market trading after the company initiated pre-packaged restructuring process with support of key lenders.</li>
<li>Prestige Wealth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWM#NASDAQ">PWM</a>) climbed 64.1% to $0.58 in pre-market trading.</li>
<li>Argo Blockchain plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) rose 41.2% to $0.2640 in pre-market trading after falling around 49% on Monday.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) gained 35.6% to $5.17 in pre-market trading after dipping over 5% on Monday.</li>
<li>Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) gained 14% to $0.89 in pre-market trading after falling 5% on Monday.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) surged 11.2% to $3.29 in pre-market trading after gaining 28% on Monday.</li>
<li>Jyong Biotech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MENS#NASDAQ">MENS</a>) jumped 10.2% to $9.37 in pre-market trading. Jyong Biotech recently announced the closing of $20 million initial public offering.</li>
<li>BigBear.ai Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NASDAQ">BBAI</a>) gained 6.7% to $7.24 in pre-market trading after climbing over 16% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Wag! Group Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares tumbled 19.3% to $0.1865 in pre-market trading after jumping 120% on Monday.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) fell 19.1% to $0.0935 in pre-market trading. Globavend and Strawberrynet Cosmetics, on Monday, executed a strategic partnership.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) dipped 18.7% to $4.31 in pre-market trading after jumping 72% on Monday.</li>
<li>RedCloud Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCT#NASDAQ">RCT</a>) dipped 18% to $2.46 in pre-market trading after falling 7% on Monday.</li>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) declined 17.3% to $1.15 in pre-market trading after gaining around 15% on Monday.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) declined 17.2% to $4.20 in pre-market trading. Applied DNA recently conducted a 27% workforce reduction and ceased operations at Applied DNA Clinical Lab.</li>
<li>Artelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) fell 16.6% to $11.07in pre-market trading. Artelo Biosciences shares jumped 96% on Monday after the company announced data from its first-in-human study for ART26.12.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) fell 14.5% to $2.89 in pre-market trading after gaining 93% on Monday.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares fell 12.9% to $8.30 in pre-market trading after the company announced the pricing of $200.0 million public offering of common stock.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) fell 6.6% to $59.70 in pre-market trading. Progress Software posted better-than-expected earnings for the second quarter, while sales missed estimates. The company also raised its guidance for FY2025.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

APDN

ARBK

ARTL

BBAI

BGLC

DTCK

GNLN

IPDN

MENS

MSPR

OGEN

PRGS

SYTA

TZUP

WOLF

Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Macro Economic Events

Econ #s

Economics

Eurozone Consumer Price Index (YoY) Preliminary For June 2.0% Vs. 2.0% Est.; 1.9% Prior

Eurozone Consumer Price Index (MoM) Preliminary For June 0.3% Vs. 0.0% Prior

Eurozone Core Consumer Price Index (YoY) Preliminary For June 2.3% Vs. 2.3% Est.; 2.3% Prior

U.K. Manufacturing Purchasing Managers Index For June 47.7 Vs. 47.7 Est.; 46.4 Prior

Shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) declined 4.78% during Tuesday pre-market session after CEO Elon Musk reignited political comeback rumors following his criticism of President Donald Trump&#8216;s spending bill.
What Happened: Late Monday, Musk expressed his disapproval of the spending bill on social media platform X, stating, &#8220;If this insane spending bill passes, the America Party will be formed the next day.&#8221; He further criticized the existing political system, calling for alternative parties to give Americans a voice.
Musk&#8217;s criticism of the bill, which he claims&nbsp;would increase the U.S. debt&nbsp;ceiling by $5 trillion, extends to both Republicans and Democrats. He also warned politicians supporting the bill that they would lose their primaries next year.
President Trump responded to Musk&#8217;s criticism by suggesting that the Tesla CEO&#8217;s empire relies heavily on federal subsidies. He stated on Truth Social, &#8220;Elon may get more subsidy than any human being in history, by far, and without subsidies, Elon would probably have to close up shop and head back home to South Africa.&#8221;
Additionally, Tesla saw over <a href="https://www.benzinga.com/markets/tech/25/07/46189042/elon-musk-led-teslas-european-woes-worsen-with-sales-down-over-60-in-sweden-and-denmark">60% plunge</a> in vehicle registrations in Denmark and Sweden during June, after witnessing strong sales in Norway. 
SEE ALSO: <a href="https://benzinga.com/crypto/25/06/46186644/bitcoin-ethereum-dogecoin-slide-even-as-q2-turns-profitable-for-crypto-analyst-warns-about-decline-in-btc-if-the-apex-coin-doesnt-close-above-this-level" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Slide Even As Q2 Turns Profitable For Crypto: Analyst Warns About Decline In BTC If The Apex Coin Doesn&#8217;t Close Above This Level</a>
Why It Matters: The spending bill and the proposed cuts have been criticized by experts and could impact Tesla and the broader automotive industry&#8217;s EV push, as it proposes axing the $7,500 federal EV credit on all new EVs sold in the U.S.
Meanwhile, investor Gary Black <a href="https://www.benzinga.com/markets/large-cap/25/06/46161226/gary-black-warns-tesla-q2-deliveries-will-disappoint-says-cheaper-models-could-cannibalize-sales-and-see-ideal-re-entry-22-below-current-levels">warned </a>that Tesla&#8217;s Q2 deliveries could fall short of estimates, potentially due to the political controversy surrounding the spending bill.
Furthermore, Tesla&#8217;s sales in Canada have reportedly dropped to nearly zero, as highlighted by researcher Troy Teslike.&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/46162850/tesla-sales-in-canada-have-dropped-to-nearly-zero-says-researcher-expects-elon-musk-led-ev-giant-may-report-losses-starting-2026">According to Teslike</a>, Tesla may start reporting GAAP losses from Q1 2026, possibly due to the political controversy and the proposed cuts in the spending bill.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46162898/elon-musk-stopped-believing-in-mars-dream-as-a-political-project-in-2024-says-peter-theil-amid-woke-ai-and-socialist-government-fears">Elon Musk Stopped Believing In Mars Dream As A &#8216;Political Project&#8217; In 2024, Says Peter Thiel Amid &#8216;Woke AI&#8217; And &#8216;Socialist Government&#8217; Fears</a> </li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tesla Stock Falls Nearly 5% In Tuesday Pre-Market: What's Going On?

GNTA

Genenta Reports Emerging Survival Signals In GBM Study; 2-Year Survival Doubles Vs Historical Data; No New Safety Concerns With Temferon

Inmarsat Maritime, a Viasat company, has announced that orders for NexusWave have exceeded 1,000-vessels. Following months of rigorous development and testing, the service has gained incredible momentum in its first six months on the market with global customers adopting NexusWave for their fleets. This milestone underscores the global shipping industry's strong appetite for a fully managed, high-speed, bonded connectivity service that combines the power of multiple networks with the convenience of a single provider.
Early adopters such as "K" Line, Anthony Veder, Mitsui O.S.K. Lines, Solvang, Sallaum Lines, Parlevliet &amp; van der Plas Group and others are already reaping the benefits of transforming their vessels into floating offices and homes.
Inmarsat's NexusWave brings together Global Xpress (GX) Ka-band, low-Earth orbit (LEO), coastal LTE, and resilient L-band services into a seamless, fully managed solution. Inmarsat's unique ‘network-bonding' technology is designed to allow connected applications to harness the aggregate speed and capacity of all available networks simultaneously rather than relying on one at a time.
Recent real-world tests have demonstrated NexusWave's exceptional performance, achieving download speeds of up to 340 megabits per second (Mbps) and upload speeds of up to 80 Mbps. Network availability on vessels has consistently exceeded 99.9%, and video call quality has remained virtually unaffected by the availability or performance of any single network. Inmarsat's solution dynamically adjusts traffic routing to maintain a seamless user experience, even in connectivity hotspots.
Users also benefit from unlimited data, global coverage, and secure-by-design infrastructure, providing complete ‘connected confidence'. For seafarers onboard it means they can enjoy a wide range of applications, including web browsing, streaming, gaming, video and voice calling, messaging, and social media access, providing a ‘home-like' connectivity experience while at sea.

VSAT

Inmarsat's NexusWave Hits 1,000-Vessel Milestone, Bringing Home-Like Wi-Fi to Ships Worldwide

Accenture Acquires Germany-Based SYSTEMA To Boost Semiconductor, High-Tech Automation Capabilities In Europe; No Terms Disclosed

S&amp;P Dow Jones Indices ("S&amp;P DJI"), the world's leading index provider, today announced its plans to collaborate with Centrifuge, a decentralized infrastructure provider specializing in real-world asset (RWA) integration, to enter the fund tokenization space by licensing the S&amp;P 500 Index. This initiative extends the reach of the S&amp;P 500 into onchain investment products and protocols.
&nbsp;
For 125 years and counting, S&amp;P DJI's indices have provided a liquid foundation for increased adoption of index-based investing around the world. By licensing&nbsp;Centrifuge to provide exposure and bring the S&amp;P 500 Index onchain, a blockchain-native investment vehicle will for the first time be built, governed, and accessed directly through Centrifuge's RWA infrastructure, rather than via traditional brokerages. Anemoy Capital, a web3 native asset manager powered by Centrifuge, has been licensed by S&amp;P DJI along with Janus Henderson, a leading global asset manager, as the sub-advisor for the fund, to offer the Janus Henderson Anemoy S&amp;P 500 Index Fund Segregated Portfolio, which is planned to launch later this year subject to regulatory approval.

SPGI

S&P 500 Goes Onchain as S&P Dow Jones Partners With Centrifuge for Fund Tokenization

Li Auto Delivers 36,279 Vehicles In June 2025, Hits 1.33 Million Cumulative Sales; Li MEGA Leads MPV Market Above RMB500K; New BEV SUVs Li i8 And i6 Launching Soon

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ncratleos.com%2F&amp;esheet=54284350&amp;newsitemid=20250701520926&amp;lan=en-US&amp;anchor=NCR+Atleos&amp;index=1&amp;md5=d7bbde1097316865a0a6a176dfa59787">NCR Atleos</a> Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) ("Atleos"), a leader in expanding self-service financial access for financial institutions, retailers and consumers, today announced that <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdirectpay.gr%2Fen%2F&amp;esheet=54284350&amp;newsitemid=20250701520926&amp;lan=en-US&amp;anchor=DirectPay&amp;index=2&amp;md5=2e1974b7bb4c0448f1e1bdf5f354be31">DirectPay</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fixchange.gr%2Fen%2Fhomepage%2F&amp;esheet=54284350&amp;newsitemid=20250701520926&amp;lan=en-US&amp;anchor=iXchange&amp;index=3&amp;md5=5b1c5d40adca9551d3a5e1cf40585864">iXchange</a> will utilize Atleos' owned and operated ATM platform (the Cashzone Network) in Greece to allow consumers to reliably, conveniently, and securely access cash.
DirectPay is a leading financial and payments services provider with more than 1,300 agent locations throughout Greece, offering MoneyGram money transfers, bill payments, cash-to-bank deposits, and a full suite of financial services. iXchange offers its customers services including foreign currency exchange, money transfers, bill payments, and more. Both companies are part of the same group.

NATL

Atleos Expands ATM Network in Greece With DirectPay and iXchange Partnership

Nikita Bier's persistence has paid off — the <a href="https://www.benzinga.com/news/24/08/40482965/angel-investor-nikita-bier-once-displayed-a-giant-painting-of-tim-cook-overlooking-facebook-ceo-mark">entrepreneur behind</a> Gas and tbh is now the new head of product at X, the social network formerly known as Twitter.
What Happened: On Monday, Bier announced on X that he's officially taking the reins as head of product. "Ladies and gentlemen, I&#8217;ve officially posted my way to the top: I&#8217;m joining @X as Head of Product," Bier wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ladies and gentlemen, I&#39;ve officially posted my way to the top: I&#39;m joining <a href="https://twitter.com/X?ref_src=twsrc%5Etfw">@X</a> as Head of Product. &#120143; is the most important social network in the world. It&#39;s where internet culture originates and where the world&#39;s most influential people convene. Finding my community and… <a href="https://t.co/MLU16rvXIP">pic.twitter.com/MLU16rvXIP</a>
&mdash; Nikita Bier (@nikitabier) <a href="https://twitter.com/nikitabier/status/1939723101723574703?ref_src=twsrc%5Etfw">June 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Bier's journey has been a lesson in tenacity. In 2022, after Elon Musk expressed interest in acquiring Twitter, Bier pitched himself directly to Musk, posting, "@elonmusk Hire me to run Twitter as VP of Product."
See Also:&nbsp;<a href="https://in.benzinga.com/tech/25/02/43772135/ex-openai-chief-scientist-ilya-sutskevers-ai-startup-valued-at-30-billion-in-latest-funding-round-report" target="_blank" rel="noreferrer noopener">Ex-OpenAI Chief Scientist Ilya Sutskever's AI Startup Valued At $30 Billion In Latest Funding Round: Report</a>
Now, following his hiring, Bier went back and replied to his original 2022 post on the platform, saying, "Never give up."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Never give up
&mdash; Nikita Bier (@nikitabier) <a href="https://twitter.com/nikitabier/status/1939831409369374939?ref_src=twsrc%5Etfw">June 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It's Important: Bier's appointment signals Musk's ongoing push to transform X into a broader everything app. With a track record of creating viral social experiences — tbh was acquired by Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) in 2017 and Gas by Discord in 2023 — Bier could help X reinvent itself.
He also teased plans to leverage Grok, X's AI assistant, to deliver "hyper-relevant timelines" and help users better understand what's happening on the platform.
Musk acquired Twitter for <a href="https://www.benzinga.com/general/social-media/25/03/44404525/elon-musk-paid-high-price-for-twitter-but-after-years-of-declining-value-x-is-once-again-wor">$44 billion in October 2022</a> and later rebranded it as X, aiming to turn it into an "everything app" as part of his larger vision. In March 2025, Musk's artificial intelligence startup, xAI, took over his social media platform through an all-stock <a href="https://www.benzinga.com/tech/25/03/44549314/elon-musk-acquires-his-own-social-media-platform-x-through-xai-in-33-billion-deal-says-combined-entity-now-worth-80-billion">deal worth $33 billion</a>.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/01/43221770/apples-ipad-turns-15-today-heres-a-throwback-to-when-steve-jobs-explained-called-it-the-third-category-after-phones-and-notebooks" target="_blank" rel="noreferrer noopener">Apple&#8217;s iPad Turns 15 Today: Here&#8217;s A Throwback To When Steve Jobs Explained Called It The ‘Third Category&#8217; After Phones And Notebooks</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo Courtesy: Mamun_Sheikh on Shutterstock.com

Tech

Nikita Bier, The Founder Of Gas And TBH, Who Once Asked Elon Musk To Hire Him As VP Of Product At Twitter, Has Joined X: 'Never Give Up'

Earnings

Press Releases

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Health Care

Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

Unicycive Therapeutics to Present at Upcoming Investor Conferences

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

General

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Legal

INVESTOR ALERT: Investigation of Unicycive Therapeutics, Inc. (UNCY) Announced by Holzer & Holzer, LLC

Comments

Unicycive Therapeutics

Unicycive Therapeutics (UNCY) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL